Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3841967 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL29374222 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3830253-A1 | AN OMEGA-TRANSAMINASE ENZYME | University College Cork-National University of Ireland Cork (IE) | 2021-06-09 | — | — | EP | claimed |
| WO-2020025646-A1 | AN OMEGA-TRANSAMINASE ENZYME | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2020-02-06 | — | — | WO | claimed |
| EP-3604507-A1 | AN OMEGA-TRANSAMINASE ENZYME | University College Cork-National University of Ireland, Cork (IE) | 2020-02-05 | — | — | EP | claimed |
| EP-1904066-B1 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2018-05-23 | — | — | EP | claimed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | claimed |
| WO-2009019412-A1 | RACEMISATION PROCESS FOR OBTAINING (1S,4S) N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENEAMINE (SERTRALINE) | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-02-12 | — | — | WO | claimed |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. (US) | 2008-11-27 | — | — | US | claimed |
| US-7408082-B1 | Racemisation process | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2008-08-05 | — | — | US | claimed |
| EP-1651590-B1 | PROCESS FOR THE PREPARATION OF AN IMINE INTERMEDIATE | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2008-07-30 | — | — | EP | claimed |
| EP-1904066-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | Sepracor Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| US-5082970-A | Process for recycling amine isomer | PFIZER INC. (US) | 1992-01-21 | — | — | US | claimed |
| US-5061728-A | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of inflammation and as immunosuppressants | PFIZER INC. (US) | 1991-10-29 | — | — | US | claimed |
| US-4981870-A | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants | PFIZER INC. (US) | 1991-01-01 | — | — | US | claimed |
| EP-0386997-A2 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER INC. (US) | 1990-09-12 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | claimed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | claimed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | claimed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A4 38/4885MEN1 1045/4885KMT2A 365/4885 |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A4 38/4885MEN1 1045/4885KMT2A 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.